Background
Methods
Study population and design
Statistical analyses
Results
Characteristics of validation patients
Variables | Overall | C0 | C1 | C2 |
---|---|---|---|---|
(n = 1152) | (n = 619) | (n = 447) | (n = 86) | |
Follow-up (months) | 45 (25–70) | 45 (24–70) | 43 (26–68) | 59 (27–88) |
eGFR decline rate (ml/min/1.73 m2/year) | − 1.1 (− 4.6 to − 1.8) | − 1.2 (− 4.6 to − 1.6) | − 1.0 (− 4.3 to − 2.0) | − 0.25 (− 4.6 to − 3.43) |
Male (%) | 566 (49.1) | 304 (49.1) | 221 (49.4) | 41 (47.7) |
Age (years) | 35.4 ± 12.0 | 36.5 ± 12.1 | 34.3 ± 11.9* | 33.0 ± 10.6* |
Urinary protein (g/d) | 1.42 (0.72–2.62) | 1.19 (0.62–2.39) | 1.44 (0.82–2.71)* | 2.51 (1.62–3.99)** |
eGFR (ml/min/1.73 m2) | 79.12 (52.08–101.67) | 78.46 (48.37–103.41) | 81.67 (56.59–100.82) | 65.95 (47.11–91.95)* |
Hypertension (%) | 381 (33.1) | 217 (35.1) | 134 (30.0) | 30 (34.9) |
MAP (mmHg) | 95.8 ± 13.5 | 96.2 ± 13.3 | 94.9 ± 13.3 | 97.6 ± 16.2 |
Oxford classification | ||||
M1 (%) | 469/1089 (43.1) | 208/586 (35.5) | 217/425 (51.1)** | 44/78 (56.4)** |
E1 (%) | 459/1089 (42.1) | 157/586 (26.8) | 239/425 (56.2)** | 63/78 (80.8)** |
S1 (%) | 839/1089 (77.0) | 422/586 (72.0) | 363/425 (85.4)** | 54/78 (69.2) |
T1 + T2 (%) | 364/1089 (33.4) | 195/586 (33.3) | 133/425 (31.3) | 36/78 (46.2)* |
With immunosuppression (%) | 566/1078 (52.5) | 288/578 (49.8) | 210/416 (50.5) | 68/84 (81.0)** |
Crescent formation and renal outcomes
Variable | All patients | With immunosuppression | Without immunosuppression | ||||
---|---|---|---|---|---|---|---|
Events | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Primary outcome | 144 (12.5) | ||||||
C0 (n = 619) | 80 (12.9) | Reference | / | Reference | / | Reference | / |
C1 (n = 447) | 46 (10.3) | 1.07 (0.71–1.63) | 0.74 | 0.76 (0.42–1.40) | 0.38 | 1.05 (0.53–2.08) | 0.89 |
C2 (n = 86) | 18 (20.9) | 0.84 (0.41–1.73) | 0.63 | 1.09 (0.41–2.86) | 0.87 | 0.48 (0.12–1.91) | 0.30 |
C1 + C2 (n = 533) | 64 (12.0) | 1.02 (0.68–1.52) | 0.93 | 0.85 (0.49–1.49) | 0.58 | 0.88 (0.46–1.70) | 0.71 |
Secondary outcome | 162 (14.1) | ||||||
C0 (n = 619) | 89 (14.4) | Reference | / | Reference | / | Reference | / |
C1 (n = 447) | 54 (12.1) | 1.01 (0.69–1.48) | 0.97 | 0.80 (0.46–1.41) | 0.44 | 0.88 (0.49–1.60) | 0.68 |
C2 (n = 86) | 19 (22.1) | 0.77 (0.40–1.50) | 0.44 | 1.16 (0.49–2.73) | 0.74 | 0.32 (0.09–1.21) | 0.09 |
C1 + C2 (n = 533) | 73 (13.7) | 0.93 (0.64–1.33) | 0.68 | 0.86 (0.51–1.45) | 0.57 | 0.72 (0.41–1.29) | 0.27 |